The highly entrenched generic market for major depressive disorder (MDD) patients poses a challenge for branded agents attempting to gain traction in the United States. The heterogeneous responses of MDD patients to well-ingrained antidepressants and/or atypical antipsychotics provide new branded agents with the opportunity to be incorporated into the well-established drug market. Due to the very crowded and competitive MDD landscape, understanding where the current players fit in the treatment algorithm is essential.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients?
  • How have Allergan’s Fetzima (levomilnacipran) and Lundbeck / Takeda’s Trintellix (vortioxetine) been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of MDD patients receive standards of care such as SSRIs (e.g., escitalopram [Lundbeck / Allergan’s Lexapro, generics]) or newer-to- market brands within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of MDD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geography: United States

Real-world data: Longitudinal patient-level claims data analysis.

Key drugs covered: Aplenzin, Fetzima, Forfivo XL, Latuda, quetiapine, Rexulti, sertraline, Spravato, Trintellix, Vraylar

Key companies: Allergan, Almatica Pharma, Janssen Pharmaceuticals, Lundbeck, Otsuka, Sanofi, Sunovion, Takeda

Key analysis provided:

  • Brand / therapy usage across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Unipolar Depression - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Author(s): Lisa Cloonan, BA

Lisa joined Decision Resources Group in 2015 as a business insights analyst for the Central Nervous System and Ophthalmology division. In this role, she analyzes the commercial opportunities for pharmacological therapies across the psychiatry space. Prior to joining Decision Resources Group, Lisa spent 6 years in clinical stroke research at Massachusetts General Hospital. While in the clinical research field, Lisa developed an expertise in neuroimaging analysis, as well as authored and co-authored articles on the influence of white matter hyperintensity burden on stroke risk and recovery. Lisa holds bachelor of arts from Connecticut College, where her course work focused on behavioral neuroscience.


Related Reports

Unipolar Depression - Landscape & Forecast - Disease Landscape & Forecast

The unipolar depression market is crowded and highly genericized. The prominent use of selective serotonin reuptake inhibitors (SSRIs) an...

View Details

Unipolar Depression - Unmet Need - Detailed, Expanded Analysis - Treatment-Resistant Depression (US & EU) - 2020

Numerous antidepressant therapies are available to treat major depressive disorder (MDD), many of which have long been generic and are entrenched in m...

View Details

Unipolar Depression - Current Treatment - Detailed, Expanded Analysis (US)

The drug landscape for major depressive disorder (MDD) consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Ag...

View Details